Skip to content

Viscoelastic Properties of Respiratory and Peripheral Muscles of COPD Patients

Comparison of Viscoelastic Properties of Respiratory Muscles and Peripheral Muscles in Chronic Obstructive Pulmonary Disease Patients With Healthy Subjects

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06580353
Enrollment
60
Registered
2024-08-30
Start date
2024-01-01
Completion date
2024-05-01
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Muscle Tone Abnormalities

Brief summary

The aim of this study was to compare the viscoelastic properties of auxiliary respiratory muscles and peripheral muscles of chronic obstructive pulmonary disease patients with healthy subjects. Myotonometry was used to evaluate the viscoelastic properties of the muscles. The viscoelastic properties of the sternoclaidus mastoid, pectoralis major, upper trapezius, deltoid, biceps brachii, rectus femoris, gastrocinemius, and tibialis anterior muscles were evaluated.

Detailed description

muscle viscoelastic properties; muscle tone, stiffness and elasticity. These features may vary due to muscle overuse, lack of relaxation and recovery. The aim is to investigate these differences in COPD patients and healthy individuals.

Interventions

None listed

Sponsors

Gaziantep Islam Science and Technology University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* male gender, * body mass index (BMI) between 18.5-29.9 kg/m2, * stable COPD patients

Exclusion criteria

* being in the acute exacerbation period for COPD patients, * having undergone any neurological, orthopaedic or thoracic surgery, * presence of malignancy in any organ, * presence of comorbidities affecting muscle atrophy (myasthenia gravis, muscular dystrophy, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Respiratory functions (PEF)1 DayPeak expiratory flow (PEF) were measured was evaluated with spirometry. It will be recorded as liters and expected percentage
The Medical Research Council Scale1 DayPatients simply indicate on the scale the level of activity that causes dyspnoea in them according to the activities between 0-4.
The COPD Assessment Test1 DayThis statement describes a scale consisting of eight items, each with response values ranging from 0 to 5. The total score is calculated by summing the responses to all the items, resulting in a range from 0 to 40. A higher total score indicates a greater negative impact of the disease on the individual's quality of life and daily activities.
Viscoelastic properties of muscles1 DayThe viscoelastic properties of the muscles (muscle tone (Hz), and elasticity (Relative), stiffness (N/m)) were measured using a hand-held myotonometer.
Respiratory functions (FEV1)1 DayIn pulmonary function test was evaluated with spirometry. forced expiratory volume in the first second (FEV1);will be recorded as liters and expected percentage
Respiratory functions (FVC)1 DayIn pulmonary function test was evaluated with spirometry. forced expiratory volume in the first second (FEV1);will be recorded as liters and expected percentage
Respiratory functions (FEV1/FVC)1 Dayratio of forced expiratory volume in the first second to vital capacity (FEV1/FVC) was evaluated with spirometry.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026